cuct555w | Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/cuct555w_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Jia%2C_Ranran%3B_Wang%2C_Hongyun>
?:doi	<https://research.tib.eu/covid-19/entity/10.1093/cid/ciaa1325>
?:doi	10.1093/cid/ciaa1325
?:journal	Clin_Infect_Dis
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/1d6d62abdadee727129af76966faa92abc092ca1.json
?:pmc_json_files	document_parses/pmc_json/PMC7717149.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7717149>
?:pmid	<https://research.tib.eu/covid-19/entity/33244589.0>
?:pmid	33244589.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/1d6d62abdadee727129af76966faa92abc092ca1>
?:source	Medline; PMC
?:title	How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-27

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/cuct555w>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/cuct555w>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all